PMID- 12510357
OWN - NLM
STAT- MEDLINE
DCOM- 20030220
LR  - 20151119
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 60
IP  - 12
DP  - 2002 Dec
TI  - [Usefulness of serum matrix metalloproteinase-3(MMP-3) level in the diagnosis of 
      rheumatoid arthritis].
PG  - 2325-30
AB  - Matrix metalloproteinase-3 is abundantly expressed in active rheumatoid synovium, 
      and serum level of MMP-3 is a useful marker not only for the diagnosis of 
      rheumatoid arthritis but also for the evaluation of prognosis in the joint 
      destruction. It should be noted, however, that serum MMP-3 may be increased in 
      other inflammatory arthritis, thus its specificity for the diagnosis of early RA 
      may not be high enough. Recent reports indicated that methotrexate or anti-TNF 
      alpha therapy effectively suppressed the serum MMP-3 level during the course of 
      the treatment, whereas corticosteroid didn't. Thus, suppression of serum MMP-3 
      could explain the discrepancy in the inhibition of bony destruction in RA 
      patients by the therapeutic strategy.
FAU - Yamanaka, Hisashi
AU  - Yamanaka H
AD  - Institute of Rheumatology, Tokyo Women's Medical University.
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Arthritis, Rheumatoid/*diagnosis
MH  - Biomarkers/blood
MH  - Humans
MH  - Matrix Metalloproteinase 3/*blood
MH  - Prognosis
MH  - Synovial Membrane/enzymology
RF  - 19
EDAT- 2003/01/04 04:00
MHDA- 2003/02/21 04:00
CRDT- 2003/01/04 04:00
PHST- 2003/01/04 04:00 [pubmed]
PHST- 2003/02/21 04:00 [medline]
PHST- 2003/01/04 04:00 [entrez]
PST - ppublish
SO  - Nihon Rinsho. 2002 Dec;60(12):2325-30.